Product Description
Amoxicillin is used to treat certain infections caused by bacteria, such as pneumonia; bronchitis (infection of the airway tubes leading to the lungs); and infections of the ears, nose, throat, urinary tract, and skin. It is also used in combination with other medications to eliminate H. pylori, a bacteria that causes ulcers. Amoxicillin is in a class of medications called penicillin-like antibiotics. It works by stopping the growth of bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a685001.html)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Benin, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Kenya, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 9
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: COVID-19|Fractures, Open|Influenza, Human|Pneumonia|Respiratory Tract Infections|Urinary Tract Infections
Phase 2: Buruli Ulcer|Diverticulitis
Phase 1: Helicobacter Infections|Other|Short Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| LP-001 | P1 |
Completed |
Other |
2024-12-16 |
12% |
2025-02-06 |
Primary Endpoints |
| GRAAL | P1 |
Recruiting |
Short Bowel Syndrome |
2024-12-01 |
50% |
2024-11-27 |
Primary Endpoints|Treatments |
| CTR20230643 | P1 |
Completed |
Helicobacter Infections |
2023-04-28 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| BLMs4BU | P2 |
Recruiting |
Buruli Ulcer |
2026-05-31 |
12% |
2024-05-17 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| DIREBIOT | P2 |
Recruiting |
Diverticulitis |
2025-12-31 |
2025-05-02 |
Treatments |
|
| DURATIOM | P3 |
Not yet recruiting |
Fractures, Open |
2027-12-31 |
2025-05-02 |
Treatments |
|
| REMAP-CAP | P3 |
Recruiting |
COVID-19|Pneumonia|Influenza, Human |
2026-02-01 |
2024-11-27 |
||
| SEARCH | P3 |
Completed |
Pneumonia |
2024-04-05 |
2024-05-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
| CTR20131000 | P3 |
Recruiting |
Respiratory Tract Infections|Urinary Tract Infections |
None |
2025-04-29 |